First Astellus/AstraZeneca (AZN.US) blockbuster ADC therapy is poised to secure EU approval.

Market IntelSunday, Mar 2, 2025 10:00 pm ET
1min read

First and third-party and

(AZN.US) recently announced that their jointly developed antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), as a single agent for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) low-expressing or HER2-low-expressing breast cancer who have received at least one prior endocrine therapy for metastatic disease and are considered not suitable for endocrine therapy as a next-line treatment.

Enhertu is an

therapy jointly developed by AstraZeneca and Daiichi Sankyo. It is designed using Daiichi Sankyo's proprietary DXd ADC technology platform, composed of a humanized monoclonal antibody targeting HER2 linked to a topoisomerase I inhibitor payload via a tetrapeptide cleavable linker. Enhertu is the first HER2-targeting ADC with an indication not limited to a specific cancer type.

The positive opinion of CHMP was based on the results of the phase 3 clinical trial DESTINY-Breast. The results were presented at the 2024 American Society of Clinical

(ASCO) annual meeting and published in the New England Journal of Medicine. In the trial, Enhertu reduced the risk of disease progression or death by 38% compared to chemotherapy in patients with HR-positive, HER2-low-expressing metastatic breast cancer who had not received chemotherapy (HR=0.62; 95% CI, 0.52–0.75; p<0.0001), with a median progression-free survival (PFS) of 13.2 months in the Enhertu group versus 8.1 months in the chemotherapy group. In the DESTINY-Breast06 trial, the safety profile of Enhertu was consistent with previous breast cancer clinical trials, without any new safety issues.

Comments



Add a public comment...
No comments

No comments yet

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.